Drugs / Ociperlimab
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04047862 | Aug 2019 → Aug 2024 | — | BeiGene | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05267054 | Apr 2022 → Aug 2024 | diffuse large B-cell lymphoma | BeiGene | Completed | No outcome recorded |
| Phase 29 trials | ||||||
| Phase 2 | NCT05809895 | Sep 2023 → Jul 2029 | triple-negative breast carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT05577702 | Mar 2023 → Dec 2024 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05014815 | Nov 2021 → Sep 2024 | non-small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05019677 | Sep 2021 → Dec 2024 | intrahepatic cholangiocarcinoma | Fudan University | Withdrawn | No outcome recorded |
| Phase 2 | NCT04948697 | Aug 2021 → Feb 2024 | hepatocellular carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT04952597 | Jul 2021 → Jul 2023 | small cell lung carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT04732494 | Mar 2021 → Feb 2023 | esophageal squamous cell carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT04693234 | Feb 2021 → Jun 2022 | cervical cancer | BeiGene | Completed | No outcome recorded |
| Phase 2 | NCT05023109 | Feb 2021 → Jan 2023 | biliary tract cancer | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05791097 | Jul 2023 → Dec 2027 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT04866017 | Jun 2021 → Oct 2023 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT04746924 | May 2021 → May 2025 | non-small cell lung carcinoma | BeiGene | Terminated | No outcome recorded |
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-12-20 | Novartis Pharmaceuticals | Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab novartis.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ociperlimab | “Drug: Ociperlimab Ociperlimab 900mg IV Q3W” NCT05023109 ↗14“Drug: Ociperlimab Ociperlimab 900mg IV Q3W” NCT05019677 ↗ |
| Known as | BGB-A1217 | “BGB-A1217 (known as ociperlimab)” NCT04047862 ↗ |
| Action | Inhibit | “anti-TIGIT monoclonal antibody ociperlimab” PMID 37857528 ↗ Oct 2023 |
| Modality | Monoclonal antibody | “anti-TIGIT monoclonal antibody ociperlimab” PMID 37857528 ↗ Oct 2023 |
| Route | Intravenous | “Administered as an intravenous (IV) injection” NCT04047862 ↗ |
| Target | TIGIT | “binds to T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) with high affinity and specificity.” PMID 37857528 ↗ Oct 2023 |